Q-omics provides the consensus-scored ELOVL4 profile across patient tissues and cancer cell-line models. ELOVL4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ELOVL4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, ELOVL4 RNA expression shows 19,093 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, COAD, and TGCT as cancer lineages where ELOVL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOVL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOVL4 survival associations across molecular data types. ELOVL4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOVL4 RNA expression–survival associations across cancer types. High ELOVL4 expression shows unfavorable associations in BLCA, STAD, UVM, UCEC and KICH, but favorable associations in PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ELOVL4 RNA expression.
This table summarizes ELOVL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ELOVL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOVL4 shows lower tumor expression in COAD and higher tumor expression in KICH, THCA, LUSC, LUAD and CHOL. The COAD box plot shows higher ELOVL4 RNA expression in normal versus tumor tissue (log2 FC = −0.693, t-test p < 0.001).
This table shows molecular features associated with ELOVL4 in patient tissues and cancer cell lines. In patient samples, ELOVL4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ELOVL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
